Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication
Autore:
Drapalski, AL; Rosse, RB; Peebles, RR; Schwartz, BL; Marvel, CL; Deutsch, SI;
Indirizzi:
Vet Affairs Med Ctr, Mental Hlth Serv Line, Washington, DC 20422 USA Vet Affairs Med Ctr Washington DC USA 20422 ine, Washington, DC 20422 USA Georgetown Univ, Sch Med, Dept Psychiat, Washington, DC USA Georgetown Univ Washington DC USA Med, Dept Psychiat, Washington, DC USA Georgetown Univ, Interdisciplinary Program Neurosci, Washington, DC USA Georgetown Univ Washington DC USA y Program Neurosci, Washington, DC USA
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 5, volume: 24, anno: 2001,
pagine: 290 - 294
SICI:
0362-5664(200109/10)24:5<290:TIDSIA>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
NMDA INTERVENTION STRATEGY; D-CYCLOSERINE; HYPOTHESIS; PHENCYCLIDINE; MILACEMIDE; GLYCINE; TRIAL;
Keywords:
schizophrenia; glutamate; excitotoxicity; negative symptoms;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Deutsch, SI Vet Affairs Med Ctr, Mental Hlth Serv Line, 50 Irving St NW, Washington, DC 20422 USA Vet Affairs Med Ctr 50 Irving St NW Washington DC USA 20422 SA
Citazione:
A.L. Drapalski et al., "Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication", CLIN NEUROP, 24(5), 2001, pp. 290-294

Abstract

Topiramate was shown to attenuate the severity of negative symptoms (e.g.,emotional withdrawal) in a patient with schizophrenia when added to his stable regimen of antipsychotic medication. Topiramate was administered for aperiod of 12 weeks: during the first 4 weeks, dosage was adjusted to the maximal tolerated dose (i.e., 175 mg/d), and, thereafter, this dosage was maintained for 8 weeks. Topiramate was studied because of recent data and hypotheses suggesting that N-methyl-D-aspartate receptor hypofunction, dampened GABAergic inhibition, and excessive stimulation of the kainic acid (KA)/alpha -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) class of glutamate receptors occur in at least some patients with schizophrenia, especially those with persistent negative symptoms and progressive psychosocial deterioration. Topiramate is a recently approved and marketed medication for the treatment of seizure disorders, whose mechanism of action includes potentiation of GABAergic neurotransmission and antagonism of KA/AMPA glutamate receptors. This case is presented because of the dramatic response of negative symptoms to the addition of topiramate. The severity of negative symptoms was assessed formally with the Negative Scale of the Positive and Negative Syndrome Scale. The negative symptoms of schizophrenia are usually resistant to most behavioral and pharmacologic interventions.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:58:55